Sionna Therapeutics Statistics Share Statistics Sionna Therapeutics has 44.14M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 44.14M Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) 99.99% Shares Floating n/a Failed to Deliver (FTD) Shares 7,947 FTD / Avg. Volume 3.86%
Short Selling Information The latest short interest is 3.6M, so 8.16% of the outstanding
shares have been sold short.
Short Interest 3.6M Short % of Shares Out 8.16% Short % of Float 13.71% Short Ratio (days to cover) 20.61
Valuation Ratios The PE ratio is -17.2 and the forward
PE ratio is -10.1.
Sionna Therapeutics's PEG ratio is
1.17.
PE Ratio -17.2 Forward PE -10.1 PS Ratio 0 Forward PS n/a PB Ratio -6.48 P/FCF Ratio -20.09 PEG Ratio 1.17
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Sionna Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 14.49,
with a Debt / Equity ratio of -0.06.
Current Ratio 14.49 Quick Ratio 14.49 Debt / Equity -0.06 Debt / EBITDA -0.14 Debt / FCF -0.18 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.5M Employee Count 41 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 3.46, so Sionna Therapeutics's
price volatility has been higher than the market average.
Beta 3.46 52-Week Price Change n/a 50-Day Moving Average 20.12 200-Day Moving Average n/a Relative Strength Index (RSI) 55.03 Average Volume (20 Days) 206,012
Income Statement
Revenue n/a Gross Profit n/a Operating Income -70.56M Net Income -61.69M EBITDA -69.89M EBIT -70.56M Earnings Per Share (EPS) -1.45
Full Income Statement Balance Sheet The company has 37.79M in cash and 9.75M in
debt, giving a net cash position of 28.04M.
Cash & Cash Equivalents 37.79M Total Debt 9.75M Net Cash 28.04M Retained Earnings -181.09M Total Assets 352.05M Working Capital 259.2M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -52.79M
and capital expenditures -27K, giving a free cash flow of -52.81M.
Operating Cash Flow -52.79M Capital Expenditures -27K Free Cash Flow -52.81M FCF Per Share -1.24
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
